Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

AMAZING NEUROPEPTIDE

Neurodegenerative disorders (NDDs) are characterized by neuronal death in the brain. The mechanism of the neuronal death is too complicated to be fully understood, although in many NDDs, aging and neurotoxins are known risk factors. In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons. The indirect protection effect is mainly mediated by glial cells through the production of neurotrophic factor(s) and inhibition of proinflammatory mediators. By remolding the structure and improving the transfer efficiency of VIP, its nerve protective function could be further improved. Its neuroprotective action and efficacy in inhibiting a broad range of inflammatory responses make VIP or related peptides becoming a novel therapeutic method to NDDs. In this review, we aim to summarize the relationship between VIP and NDDs.

https://www.researchgate.net/publication/309491952_The_effects_of_vasoactive_intestinal_peptide_in_neurodegenerative_disorders

The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023.

https://www.globenewswire.com/news-release/2020/04/17/2017902/0/en/Neurodegenerative-Disorder-Therapeutics-Market-Global-Report-2020-to-2030-Understand-Customers-Based-on-the-Latest-Market-Research-Findings.html